CDC RISER Industry Day

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

CDC OFFICE OF ACQUISITION SERVICES

Contract Value

Not provided

Codes & Classification
Solicitation Number

75D301-TBD-RISER

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Classification Code

-

Additional Details
Set Aside

None

Place of Performance

Atlanta, Georgia, UNITED STATES

SourceSAM
Documents3
The Centers for Disease Control and Prevention (CDC), through its Office of Acquisition Services, has issued a Special Notice announcing an upcoming Industry Day for the Resources for the Improvement of Surveillance and Emergency Response Program (RISER). This event is a key component of the CDC’s ongoing efforts to strengthen the nation’s public health infrastructure, specifically by ensuring the availability and distribution of high-quality reference pathogens and critical reagents to CDC and its research partners. The RISER program is designed to support surveillance and emergency response activities, enhance technical assistance to public health laboratories, and facilitate the development of vaccines, antiviral drugs, and diagnostic tests, all with the overarching goal of minimizing the impact of bacterial, viral, and respiratory diseases in humans. The Industry Day is scheduled for Wednesday, May 13, 2026, beginning at 9:00am EDT, and will be conducted virtually via Microsoft Teams. All interested offerors are invited to participate, though technical limitations require that each offeror limit their participation to two accounts. Registration is mandatory and can be completed by submitting the RISER Questions document to [email protected]. Upon registration, offerors will receive confirmation and subsequent instructions for accessing the event. The scope of the RISER program encompasses several core objectives: 1. Production or acquisition of high-quality stocks of reference pathogens, positive controls, detection kits, genomic sequencing components, proficiency panels, and other surveillance and research reagents to directly support CDC-developed assays and surveillance platforms. 2. Reliable availability of these reagents and materials to CDC, public health laboratory partners, and approved research collaborators for the characterization of circulating and novel pathogens. 3. Sustaining the operational capacity to rapidly scale reagent acquisition, production, and distribution in response to domestic and global public health emergencies. 4. Establishment and maintenance of secure infrastructure for real-time data exchange between contractors and the CDC, including the ability to receive and process data uploads (such as genomic sequencing files and proficiency panel results) from external partners, and to transmit validated data to CDC programs for analysis or regulatory action. 5. Enabling visualization of CDC-generated analysis outputs derived from RISER-submitted laboratory data in dashboard formats, accessible through the RISER website or secure platforms. This includes integration of historical data dashboards and future analytic summaries related to genomic surveillance, reagent validation, and proficiency testing. The procurement is classified under NAICS code 325413 (In-Vitro Diagnostic Substance Manufacturing) and also references 541511 (Custom Computer Programming Services), reflecting the dual emphasis on both biological reagent production and secure, custom data management solutions. The primary place of performance is Atlanta, Georgia. This notice is issued for market research and industry engagement purposes only; it is not a solicitation and should not be interpreted as a comprehensive statement of need. An initial draft Statement of Work and supporting documentation are provided as attachments to facilitate offeror preparation for the Industry Day. The contracting entity is the CDC Office of Acquisition Services, operating under the Department of Health and Human Services. The primary point of contact for this opportunity is Adam Dwyer, with Liubov Kriel as a secondary contact; both can be reached at [email protected]. Contractors with capabilities in in-vitro diagnostic substance manufacturing, custom computer programming for secure data exchange, and rapid response logistics for public health emergencies are encouraged to review the attached materials and consider participation. The RISER program represents a significant, ongoing opportunity to contribute to national and global public health preparedness and response. For further details and to access the notice and attachments, interested parties should refer to the official posting on SAM.gov (Opportunity ID: c43ca0ab0589492399c04e9edb01f3d6).